Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana.
BACKGROUND
Malaria is a major public health problem in French Guiana, where Plasmodium vivax has become the dominant malaria species since 2000. As in others endemic areas, it is important to specify the pattern of vivax malaria relapses and to try to discriminate efficiently re-infections from relapses.


METHODS
This study was conducted in children born between January 1, 2001 and December 31, 2008 in Camopi, an Amerindian village located in the Amazon forest (n = 325), using an open cohort design. Primary and secondary attack rates of P. vivax were calculated using survival analysis. With the difference between the primary and secondary rates, this study aimed to estimate indirectly P. vivax relapse rate and evaluate its time evolution.


RESULTS
Of the 1042 malaria attacks recorded, 689 (66%) were due to P. vivax (without mixed infection). One hundred and fifty one children had their primary attack with P. vivax and 106 had their two first attacks with P. vivax. In the absence of primaquine treatment, it was shown that P. vivax relapses mainly occurred during the first three months after the first attack. Thirty percent of children never had a relapse, 42% had a relapse before the first month after primary attack, 59% before the second month and 63% before the third month.


CONCLUSIONS
This study confirmed that the relapse pattern in Camopi was compatible with the pattern described for the P. vivax Chesson (tropical) strain. In addition, due to the relapse rate time evolution, a simple arbitrary classification rule could be constructed: before 90 days after the primary attack, the secondary attack is a relapse; after 90 days, it is a re-infection. Adapted management of malaria cases based on these results could be devised.
Hanf
Matthieu
M
Centre d'Investigation Clinique - Epidémiologie Clinique Antilles Guyane CIC-EC Inserm 802, Centre Hospitalier de Cayenne, Guyane Française. matthieu.hanf@ch-cayenne.fr
Stéphani
Aurélia
A
Basurko
Célia
C
Nacher
Mathieu
M
Carme
Bernard
B
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use; D002738:Chloroquine / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005616:French Guiana / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D016780:Malaria, Vivax / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D010966:Plasmodium vivax; D011319:Primaquine / Q000627:therapeutic use; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D000962:Antimalarials; D002738:Chloroquine; D011319:Primaquine